Strategic Investment Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.56M | Buy |
14,165
+88
| +0.6% | +$18.9K | 0.22% | 59 |
|
|
2026
Q1 | $3.06M | Buy |
14,077
+7,271
| +107% | +$1.61M | 0.21% | 60 |
|
|
2025
Q4 | $1.56M | Buy |
6,806
+16
| +0.2% | +$3.65K | 0.13% | 75 |
|
|
2025
Q3 | $1.57M | Sell |
6,790
-341
| -5% | -$69.4K | 0.14% | 75 |
|
|
2025
Q2 | $1.32M | Sell |
7,131
-2,704
| -27% | -$503K | 0.13% | 81 |
|
|
2025
Q1 | $2.06M | Sell |
9,835
-359
| -4% | -$69.8K | 0.22% | 62 |
|
|
2024
Q4 | $1.81M | Buy |
10,194
+32
| +0.3% | +$5.88K | 0.19% | 71 |
|
|
2024
Q3 | $2.01M | Sell |
10,162
-31
| -0.3% | -$5.79K | 0.22% | 67 |
|
|
2024
Q2 | $1.75M | Sell |
10,193
-24
| -0.2% | -$3.98K | 0.21% | 68 |
|
|
2024
Q1 | $1.86M | Buy |
10,217
+45
| +0.4% | +$7.75K | 0.24% | 61 |
|
|
2023
Q4 | $1.58M | Sell |
10,172
-638
| -6% | -$93K | 0.23% | 66 |
|
|
2023
Q3 | $1.61M | Buy |
10,810
+43
| +0.4% | +$6.31K | 0.27% | 55 |
|
|
2023
Q2 | $1.45M | Buy |
10,767
+91
| +0.9% | +$13.3K | 0.2% | 50 |
|
|
2023
Q1 | $1.7M | Sell |
10,676
-606
| -5% | -$92.6K | 0.31% | 53 |
|
|
2022
Q4 | $1.82M | Sell |
11,282
-4
| -0% | -$613 | 0.38% | 47 |
|
|
2022
Q3 | $1.51M | Buy |
11,286
+172
| +2% | +$24.7K | 0.34% | 53 |
|
|
2022
Q2 | $1.7M | Sell |
11,114
-31
| -0.3% | -$4.74K | 0.34% | 50 |
|
|
2022
Q1 | $1.81M | Sell |
11,145
-2,802
| -20% | -$407K | 0.34% | 52 |
|
|
2021
Q4 | $1.89M | Buy |
13,947
+569
| +4% | +$67.2K | 0.36% | 52 |
|
|
2021
Q3 | $1.44M | Buy |
13,378
+1,783
| +15% | +$204K | 0.32% | 63 |
|
|
2021
Q2 | $1.31M | Buy |
11,595
+3,248
| +39% | +$366K | 0.3% | 69 |
|
|
2021
Q1 | $903K | Buy |
8,347
+1,215
| +17% | +$130K | 0.23% | 88 |
|
|
2020
Q4 | $764K | Sell |
7,132
-2,337
| -25% | -$225K | 0.22% | 91 |
|
|
2020
Q3 | $828K | Sell |
9,469
-1,174
| -11% | -$111K | 0.28% | 68 |
|
|
2020
Q2 | $1.04M | Buy |
10,643
+673
| +7% | +$59.3K | 0.39% | 55 |
|
|
2020
Q1 | $760K | Buy |
9,970
+435
| +5% | +$37.1K | 0.35% | 61 |
|
|
2019
Q4 | $844K | Buy |
9,535
+314
| +3% | +$26.1K | 0.35% | 61 |
|
|
2019
Q3 | $698K | Buy |
9,221
+1,167
| +14% | +$80K | 0.33% | 58 |
|
|
2019
Q2 | $586K | Buy |
8,054
+2,222
| +38% | +$175K | 0.32% | 59 |
|
|
2019
Q1 | $470K | Buy |
5,832
+933
| +19% | +$76.3K | 0.32% | 62 |
|
|
2018
Q4 | $452K | Buy |
+4,899
| New | +$431K | 0.41% | 56 |
|
Other funds holding ABBV
Strategic Investment Advisors's ABBV Position: Q2 2026 in Review
Strategic Investment Advisors increased its AbbVie (ABBV) stake by 0.63% in Q2 2026, buying an estimated $18.9K and bringing the position to 14,165 shares worth $3.56M. The position accounts for 0.22% of the portfolio, ranked #59.
Strategic Investment Advisors first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. 4,232 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Strategic Investment Advisors held 14,165 shares of AbbVie worth $3.56M as of Q2 2026.
- Strategic Investment Advisors bought 88 AbbVie shares in Q2 2026, an estimated $18.9K.
- AbbVie made up 0.22% of Strategic Investment Advisors's portfolio in Q2 2026, its #59 holding.
- Strategic Investment Advisors first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- 4,232 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Strategic Investment Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.